Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2018-12-14 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about presenting clinical data at a congress, which is typical for an 'Other Events' disclosure under Item 8.01 of Form 8-K. The document does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. It is not a certification or a voting result announcement. The length is 3742 characters, which is relatively short and consistent with a current report filing. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings like Form 8-K that do not fit other specific categories.
2018-12-14 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2018, by Leap Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a lease agreement for office space. The document includes details about the lease terms, rent obligations, and a security deposit. There are no financial statements or quarterly/annual financial results presented. The document is a current report disclosing a material event rather than a financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2018-11-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2018, by Leap Therapeutics, Inc. It reports the company's financial results for the quarter ended September 30, 2018, and provides an update on product development since the end of Q2 2018. The document states that the full text of the press release is furnished as an exhibit and that the information is not incorporated by reference into other filings. The document is relatively short (4114 characters) and primarily serves as a current report announcing financial results and operational updates, typical of an Earnings Release. It is not a full quarterly or annual report, nor a detailed management discussion, but an initial announcement of quarterly financial results. Therefore, the appropriate classification is Earnings Release (ER).
2018-11-09 English
10-Q
Interim / Quarterly Report 9M 2018
2018-11-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting "Other Events" specifically a press release about presenting cancer data at a conference. There are no financial statements or detailed financial data included. The document is short (3588 characters) and primarily serves as an announcement of an event and a press release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other categories.
2018-10-22 English
SC 13D/A
Major Shareholding Notification
2018-09-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.